Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major
cause of transplant-related mortality. Some of these infections are preventable by …

Hematopoietic cell transplantation is a curative treatment for a variety of hematologic
diseases. Advances in transplantation technology have reduced early transplant-related …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

The risk of cervical cancer (CC) among women immunosuppressed for a variety of reasons
is well documented in the literature. Although there is improved organ function, quality of life …

Tumor necrosis factor (TNF) blockers are widely used to treat rheumatoid arthritis and other
chronic inflammatory diseases. Many studies have demonstrated an increased risk of …

Human papillomavirus (HPV), a member of the Papillomaviridae family, is a small (8kb),
nonenveloped, double‐stranded DNA virus. HPV has a predilection for infecting cutaneous …

Hematopoietic stem cell transplant (HCT) recipients have a substantial risk of developing
secondary solid cancers, particularly beyond 5 years after HCT and without reaching a …

At mucosal sites, papillomavirus genomes can persist in the epithelial basal layer following
immune-mediated regression. Subsequent T-cell depletion stimulates a 3-to 5-log increase …

More than 25 000 allogeneic hematopoietic stem cell transplantations (allo-HCTs) are
expected to be performed worldwide in 2010, a number that has been increasing yearly …

Patients lose protective immunity to vaccine-preventable diseases after haematopoietic stem
cell transplantation (HSCT). Therefore, revaccination of HSCT recipients represents an …